Incretin Atlas › Trials › ACHIEVE-2 (vs dapagliflozin)
ACHIEVE-2 (vs dapagliflozin)
Orforglipron · t2d
Design
- Molecule(s)
- Orforglipron
- Population
- t2d
- Official title
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2024-01 → 2025-09
- Participants
- 962
- Duration
- 40 weeks
- Registry
- NCT06192108
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| orforglipron 3 mg vs dapagliflozin 10 mg (active) | t2d | 40 | 240 | — | —−3.5 % estimand not specified | −1.3 | — | — | 19.6 | 7.9 | 3.3 | — | verified |
| orforglipron 12 mg vs dapagliflozin 10 mg (active) | t2d | 40 | 241 | — | —−6.3 % estimand not specified | −1.7 | — | — | 17.8 | 8.3 | 5.8 | — | verified |
| orforglipron 36 mg vs dapagliflozin 10 mg (active) | t2d | 40 | 241 | — | —−7.3 % estimand not specified | −1.7 | — | — | 22.4 | 12.0 | 4.1 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- orforglipron 3 mg: Active comparator dapagliflozin 10 mg: HbA1c -0.76, weight -3.0 %, AE withdrawal 0.0 %, nausea 1.7 %, vomiting 1.7 %, SAE 4.6 %. Estimand not stated in the registry record. AE discontinuation of the study drug is not reported; the registry gives withdrawal from the study for adverse events (not shown on the axis).
- orforglipron 12 mg: Active comparator dapagliflozin 10 mg: HbA1c -0.76, weight -3.0 %, AE withdrawal 0.0 %, nausea 1.7 %, vomiting 1.7 %, SAE 4.6 %. Estimand not stated in the registry record. AE discontinuation of the study drug is not reported; the registry gives withdrawal from the study for adverse events (not shown on the axis).
- orforglipron 36 mg: Active comparator dapagliflozin 10 mg: HbA1c -0.76, weight -3.0 %, AE withdrawal 0.0 %, nausea 1.7 %, vomiting 1.7 %, SAE 4.6 %. Estimand not stated in the registry record. AE discontinuation of the study drug is not reported; the registry gives withdrawal from the study for adverse events (not shown on the axis).
Verbatim quotes from the source (15)
- orforglipron 3 mg · weight_unsp · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 3 mg: HbA1c -1.32; body weight -3.5 %; withdrawals for adverse events 3/240
- orforglipron 3 mg · hba1c · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 3 mg: HbA1c -1.32; body weight -3.5 %; withdrawals for adverse events 3/240
- orforglipron 3 mg · nausea · CT.gov adverse events, Other events: Nausea
"groupId": "EG000", "numEvents": 60, "numAffected": 47, "numAtRisk": 240
- orforglipron 3 mg · vomiting · CT.gov adverse events, Other events: Vomiting
"groupId": "EG000", "numEvents": 22, "numAffected": 19, "numAtRisk": 240
- orforglipron 3 mg · sae · CT.gov event groups
"id": "EG000", "title": "Orforglipron 3 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated at week 4 to a dose of 3 mg, which was then maintained up
- orforglipron 12 mg · weight_unsp · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 12 mg: HbA1c -1.74; body weight -6.3 %; withdrawals for adverse events 3/241
- orforglipron 12 mg · hba1c · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 12 mg: HbA1c -1.74; body weight -6.3 %; withdrawals for adverse events 3/241
- orforglipron 12 mg · nausea · CT.gov adverse events, Other events: Nausea
"groupId": "EG001", "numEvents": 57, "numAffected": 43, "numAtRisk": 241
- orforglipron 12 mg · vomiting · CT.gov adverse events, Other events: Vomiting
"groupId": "EG001", "numEvents": 34, "numAffected": 20, "numAtRisk": 241
- orforglipron 12 mg · sae · CT.gov event groups
"id": "EG001", "title": "Orforglipron 12 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4 and 6 mg at week 8) unti
- orforglipron 36 mg · weight_unsp · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 36 mg: HbA1c -1.73; body weight -7.3 %; withdrawals for adverse events 6/241
- orforglipron 36 mg · hba1c · ClinicalTrials.gov results tables
ClinicalTrials.gov results, Orforglipron 36 mg: HbA1c -1.73; body weight -7.3 %; withdrawals for adverse events 6/241
- orforglipron 36 mg · nausea · CT.gov adverse events, Other events: Nausea
"groupId": "EG002", "numEvents": 70, "numAffected": 54, "numAtRisk": 241
- orforglipron 36 mg · vomiting · CT.gov adverse events, Other events: Vomiting
"groupId": "EG002", "numEvents": 50, "numAffected": 29, "numAtRisk": 241
- orforglipron 36 mg · sae · CT.gov event groups
"id": "EG002", "title": "Orforglipron 36 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4, 6 mg at week 8, 12 mg a
Primary sources
- Eli Lilly and Company. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2) (ACHIEVE-2). ClinicalTrials.gov identifier NCT06192108. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06192108
- Eli Lilly and Company. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2) (ACHIEVE-2). ClinicalTrials.gov identifier NCT06192108. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06192108
How to cite this page
Medical Adviser's Group. Incretin Atlas: ACHIEVE-2 (vs dapagliflozin). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.